Grown Rogue International (GRUSF) Income from Continuing Operations (2009 - 2026)
Grown Rogue International (GRUSF) posted quarterly Income from Continuing Operations of 2213391.0 for Q1 2026, down 397.95% year-over-year from 742870.0 in Q1 2025, and up 100.0% quarter-over-quarter from 6493305116762.0 in Q4 2025.
Grown Rogue International (GRUSF) Income from Continuing Operations (2009 - 2026) Analysis & Trends
Grown Rogue International's Income from Continuing Operations history runs 18 years deep, the most recent figure standing at 2213391.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 397.95% year-over-year to 2213391.0; the TTM figure through Mar 2026 stood at 3504540408141.0 (down 134.9% YoY), while the FY2025 annual figure was 2116762.0, down 164.78% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 2213391.0, up from 6493305116762.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 10042989267604.0 in Q4 2024, with the low at 6493305116762.0 in Q4 2025.
- The 5-year median for Income from Continuing Operations is 379789.39 (2023), against an average of 435896098855.0.
- The sharpest annual moves came in 2025 and 2026: Income from Continuing Operations surged 2727625228.55% in 2025, then plunged 397.95% in 2026.
- Grown Rogue International's Income from Continuing Operations stood at 638291.0 in 2022, then sank by 265.44% to 1055966.0 in 2023, then surged by 951071371.95% to 10042989267604.0 in 2024, then plunged by 164.66% to 6493305116762.0 in 2025, then soared by 100.0% to 2213391.0 in 2026.
- Business Quant data shows GRUSF's Income from Continuing Operations at 2213391.0 in Q1 2026, 6493305116762.0 in Q4 2025, and 2988765000000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Grown Rogue International | 110.47 Mn | 98.93 Mn | 5.37 Mn | -1.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.48 Mn |
| Mar 31, 2026 | -2.21 Mn |
| Dec 31, 2025 | -6,493.31 Bn |
| Sep 30, 2025 | 2,988.77 Bn |
| Jun 30, 2025 | 1.92 Mn |
| Mar 31, 2025 | 742,870.00 |
| Dec 31, 2024 | 10,042.99 Bn |
| Sep 30, 2024 | -109,573.89 |
| Jun 30, 2024 | -4.73 Mn |
| Mar 31, 2024 | -3.42 Mn |
| Dec 31, 2023 | -1.06 Mn |
| Oct 31, 2023 | -1.49 Mn |
| Jul 31, 2023 | 379,789.39 |
| Apr 30, 2023 | 851,897.00 |
| Jan 31, 2023 | 821,063.00 |
| Jan 31, 2022 | 638,291.00 |
| Oct 31, 2021 | 1.62 Mn |
| Jul 31, 2021 | 764,360.00 |
| Apr 30, 2021 | -586,589.00 |
| Jan 31, 2021 | 978,539.00 |